BioFire Boosts BioMerieux Q1 Revenues; Biodefense Contract on Hold due to Focus Dx Legal Protest | GenomeWeb

NEW YORK (GenomeWeb) — BioMérieux said this week that its first quarter revenues increased 3 percent year over year but 8 percent when including sales from recent acquisition BioFire Diagnostics and at constant exchange rates.

In addition, PCR Insider has learned that a contract awarded by the US military to recently formed BioMérieux subsidiary BioFire Defense to develop a biothreat detection platform has been put on hold due to a formal legal protest by Focus Diagnostics, which competed with BioMérieux for the contract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.